Abbott Laboratories
Abbott Laboratories (ABT)
Overview
Abbott Laboratories is a diversified American health care company headquartered in Abbott Park, Illinois, that develops, manufactures, and sells medical devices, diagnostic products, nutritional products, and branded generic pharmaceuticals. It operates in the health care sector and trades on the NYSE under the ticker ABT, with products sold in more than 160 countries. Founded in 1888, Abbott has grown into a roughly $44.3 billion revenue company (fiscal 2025) with approximately 115,000 employees worldwide, and it is one of the largest and most diversified health care companies in the S&P 500, spanning everything from continuous glucose monitors and heart devices to infant formula and diagnostic testing equipment.
What They Do & How They Make Money
Abbott's business model is built on selling a broad portfolio of health-related products across four distinct end markets rather than concentrating on a single therapeutic area. In medical devices, the company designs and manufactures products such as the FreeStyle Libre continuous glucose monitoring system, heart devices (structural heart repair tools like MitraClip, pacemakers, and heart failure devices from its St. Jude Medical acquisition), and other devices used in hospitals and by patients directly; it earns recurring revenue both from device/hardware sales and, notably with FreeStyle Libre, from ongoing consumable sensor sales that create a razor-and-blades style revenue stream. In diagnostics, Abbott sells laboratory testing instruments and reagents to hospitals, labs, and blood banks, and also makes rapid/point-of-care and molecular diagnostic tests, generating revenue through both equipment placements and the ongoing sale of testing consumables. Its nutrition business manufactures and sells branded nutritional products — infant formula (Similac), adult and medical nutrition shakes (Ensure, Glucerna), and pediatric electrolyte products (Pedialyte) — sold through retail and health care channels worldwide, particularly in fast-growing international markets. Finally, its established pharmaceuticals segment sells off-patent, branded generic medicines primarily in emerging markets outside the United States, capitalizing on Abbott's trusted brand name and distribution network in countries where branded generics still command premium positioning over unbranded generics.
Business Segments
Abbott reports four operating segments. Based on fiscal 2025 results:
- Medical Devices (~48% of revenue, roughly $21.4 billion): The largest and fastest-growing segment, up nearly 13% year over year, driven heavily by FreeStyle Libre glucose monitoring sales alongside cardiovascular, neuromodulation, and diabetes care devices.
- Diagnostic Products (~20% of revenue, roughly $8.9 billion): Includes core laboratory diagnostics, molecular diagnostics, point-of-care testing, and rapid diagnostics; this segment declined roughly 4% in 2025 as COVID-19-related testing revenue continued to fade from prior-year comparisons.
- Nutritional Products (~19% of revenue, roughly $8.5 billion): Covers pediatric nutrition (Similac, PediaSure) and adult nutrition (Ensure, Glucerna), with relatively flat growth in 2025.
- Established Pharmaceutical Products (~12% of revenue, roughly $5.5 billion): Branded generic pharmaceuticals sold mainly in emerging markets, up nearly 7% in 2025.
Competitors
Abbott's competitive landscape varies substantially by segment:
- Medical Devices: Medtronic and Boston Scientific in cardiovascular and structural heart devices; Dexcom is Abbott's most direct rival in continuous glucose monitoring (FreeStyle Libre vs. Dexcom's G-series sensors), with Medtronic also present in diabetes devices.
- Diagnostic Products: Roche Diagnostics, Danaher (through Beckman Coulter and Cepheid), Siemens Healthineers, and Becton Dickinson compete across laboratory and point-of-care diagnostics.
- Nutritional Products: Nestlé (Gerber, Boost) and Reckitt Benckiser/Mead Johnson (Enfamil) are Abbott's principal rivals in infant formula and adult nutrition shakes.
- Established Pharmaceuticals: Generic and branded-generic drug makers such as Teva, Sanofi, and various regional pharmaceutical companies compete in Abbott's emerging-market pharmaceutical business.
Competitive Position
Abbott's key competitive advantage is the breadth and balance of its four-segment portfolio, which reduces reliance on any single product cycle, therapeutic area, or geography and gives management flexibility to reallocate capital toward its fastest-growing opportunities. The standout asset in its current portfolio is FreeStyle Libre, which has become one of the most successful medical device product launches in the industry, growing into a multibillion-dollar franchise by expanding continuous glucose monitoring beyond insulin-dependent diabetics to a much larger population of type 2 diabetics and even non-diabetic consumers interested in metabolic health — a market Abbott essentially helped create and now leads alongside Dexcom. Abbott's nutrition and established pharmaceuticals businesses, while slower-growing, provide steady cash flow and deep emerging-market distribution relationships (particularly in Latin America, India, and Southeast Asia) that are difficult and slow for competitors to replicate. The diagnostics business, while currently soft as pandemic-era testing revenue normalizes, still gives Abbott a large, sticky installed base of laboratory instruments that generate recurring reagent and consumable sales.
Key risks include intensifying competition in glucose monitoring as Dexcom, Medtronic, and newer entrants push into the same rapidly growing CGM market that has been Abbott's biggest growth driver, raising the risk of price competition or share erosion over time. Reputational and legal risk is also present: Abbott faced significant litigation over its Similac infant formula tied to necrotizing enterocolitis (NEC) claims and a 2022 manufacturing-related recall and temporary plant shutdown at its Sturgis, Michigan facility, which triggered a U.S. infant formula shortage and drew regulatory scrutiny — both episodes that damaged trust in a historically strong brand and generated ongoing product liability litigation. More broadly, Abbott's diagnostics segment remains exposed to unpredictable swings in infectious-disease testing demand, its nutrition and pharma businesses carry currency and emerging-market economic risk given their international revenue mix, and the medical device business faces the typical risks of reimbursement policy changes, regulatory approval timelines, and pricing pressure from health systems and payers.